Mar­ket­ingRx roundup: Bio­gen be­gins so­cial aware­ness around post­par­tum de­pres­sion; Phar­ma mar­keters in the NBA games

As Bio­gen and Sage Ther­a­peu­tics await an FDA de­ci­sion on post­par­tum de­pres­sion (PPD) can­di­date zu­ra­nolone, they’re tak­ing the first steps to dri­ve aware­ness of the con­di­tion. A so­cial me­dia ad on Face­book di­rects users to a Bio­gen land­ing page fea­tur­ing one of its own em­ploy­ees named Caitlin, a young moth­er who tells her sto­ry of PPD af­ter her first child was born sev­er­al years ago.

A Bio­gen spokesper­son clar­i­fied that the work is not part of a broad­er cam­paign but is more in line with the im­por­tance of high­light­ing sto­ries in men­tal health — in this case for women liv­ing with PPD.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER